Publications by authors named "Xiangao Sun"

Background: The development of gene interfering RNA (iRNA) molecules such as small interfering RNAs (siRNAs) and antagomirs provides promising therapeutic modalities for targeting specific mRNAs and microRNAs (miRNAs) involved in disease mechanisms. Therapeutic iRNA strategy against cancer or hypermutable viruses prefers targeting multiple genes simultaneously to achieve synergistic inhibition and to prevent resistance.

Methods: In the present study, we report chemically synthesized, multi-target gene interfering RNA structures based upon branched, tripodal interfering RNAs (termed T-tiRNAs).

View Article and Find Full Text PDF
Article Synopsis
  • Small interfering RNAs (siRNAs) are short, double-stranded RNAs that silence genes using the RNA interference (RNAi) pathway, but the common 19+2 structure can lead to unwanted nonspecific effects.
  • Researchers have identified a new type of siRNA called asymmetric shorter-duplex siRNAs (asiRNAs) that have shorter duplex regions and can still effectively silence genes while minimizing these nonspecific effects.
  • The study suggests that asiRNAs could be a valuable alternative to traditional siRNAs for both research purposes and therapeutic treatments.
View Article and Find Full Text PDF

RNA interference (RNAi) has become an indispensable technology for biomedical research and has demonstrated the potential to become a new class of therapeutic. Current RNAi technology in mammalian cells relies on short interfering RNA (siRNA) consisting of symmetrical duplexes of 19-21 base pairs (bp) with 3' overhangs. Here we report that asymmetric RNA duplexes with 3' and 5' antisense overhangs silence mammalian genes effectively.

View Article and Find Full Text PDF

Most efforts thus far have been devoted to develop apoptosis inducers for cancer treatment. However, apoptotic pathway deficiencies are a hallmark of cancer cells. We propose that one way to bypass defective apoptotic pathways in cancer cells is to induce necrotic cell death.

View Article and Find Full Text PDF

Most chemotherapeutic drugs kill cancer cells by indirectly activating checkpoint-mediated apoptosis after creating nonselective damage to DNA or microtubules, which accounts for their toxicity toward normal cells. We seek to target cancer cells by directly activating checkpoint regulators without creating such damage. Here, we show that beta-lapachone selectively induces apoptosis in cancer cells without causing the death of nontransformed cells in culture.

View Article and Find Full Text PDF